Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies
Study Details
Study Description
Brief Summary
A Phase I, open-label clinical pharmacology study designed to evaluate the effect of tipifarnib on cardiac repolarization (corrected QT interval [QTc] duration) following a single dose of 900 mg and after repeated twice daily administration of 600 mg in subjects with advanced solid malignancies. Subjects will receive a 900 mg single dose at cycle 1 day 1 follow by 600 mg twice a day orally with a meal (Days 2-7 and 15-21) in 28-day cycles. Beginning on Day 2 of Cycle 1, subjects will self-administer 600 mg tipifarnib, orally with a meal, bid for 7 days in alternating weeks (Days 2-7 and 15-21) in 28-day cycles. The secondary objectives are to evaluate the safety and PK of tipifarnib. Series of PK will be collected on day -1 of Cycle 1, Cycle 1 day 1 and Cycle 1 day 7.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Detailed Description
Phase I study will evaluate the effect of tipifarnib on cardiac repolarization (corrected QT interval [QTc] duration) following a single dose of 900 mg and after repeated twice daily administration of 600 mg in subjects with advanced solid malignancies. The study will enroll approximately 20 subjects with advanced solid malignancies (at least 8, but no more than 12, male subjects). Subjects must have no approved/appropriate therapeutic options available. Subject will undergo series of ECG at Cycle 1 day -1 follow by study drug dosing, series of Pharmacokinetic and ECG at Cycle 1 day 1 and Cycle 1 day 7. Beginning on Day 2 of Cycle 1, subjects will self-administer 600 mg tipifarnib, orally with a meal, bid for 7 days in alternating weeks (Days 2-7 and 15-21) in 28-day cycles. For Cycle 2 and beyond, subjects will self-administer 600 mg bid on Days 1-7 and Days 15-21 in 28-day cycles.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: Single Group Assignment Single Arm - Drug administered on Days 1-7 and Days 15-21 of a 28-day treatment cycle. Series of Pharmacokinetics and ECGs will be done during cycle 1. |
Drug: Tipifarnib
Cardiac Safety of Tipifarnib
|
Outcome Measures
Primary Outcome Measures
- The change from baseline in time-matched difference in QTc interval to post-baseline time points after a single 900 mg dose and multiple 600 mg BID doses of tipifarnib in subjects with Advanced Solid Malignancies [7 days]
The analysis will be performed using the concentration-QTc modeling approach (Garnett 2018) and the by-time point modeling approach defined in the International Council on Harmonisation (ICH) E14 guidance. The analysis will be performed using triplicate, time-matched ECG measurements of the QTc interval will be taken at baseline, Day 1 (900 mg tipifarnib) and Day 7 (600 mg tipifarnib BID) at predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post dose (24 hour on day 1 only).
Secondary Outcome Measures
- Investigate safety and tolerability of tipifarnib according to NCI CTCAE v5.0 [30 days after treatment discontinuation]
Incidence of adverse events, incidence of abnormal laboratory test results, abnormal vital signs, and abnormal ECG results
Eligibility Criteria
Criteria
Inclusion Criteria:
-
At least 18 years of age.
-
Advanced solid tumor malignancies for whom no other therapy or intervention is available
-
Confirmation of measurable disease by RECIST v1.1
-
No uncontrolled hypertension, defined as >140/90 mm Hg
-
A normal 12-lead ECG
-
At least two weeks since the last systemic anticancer therapy regimen prior to Cycle 1 Day 1; this includes radiation therapy.
-
ECOG performance status of 0-2.
-
Acceptable liver, renal and hematological function
-
Other protocol defined inclusion criteria may apply.
Exclusion Criteria
-
Has disease that is suitable for therapy administered with curative intent.
-
Ongoing treatment with another anticancer agent indicated for the malignancy for which the subject is enrolling into the study (excluding adjuvant hormonal therapy for breast cancer and hormonal treatment for castration sensitive prostate cancer).
-
History of cardiomyopathy, unstable angina within prior 6 months, myocardial infarction within prior 6 months, cerebrovascular attack within prior 6 months, history of New York Heart Association grade III or greater congestive heart failure, or current serious cardiac arrhythmia requiring medication.
-
Non-tolerable Grade 2 or ≥ Grade 3 neuropathy or evidence of unstable neurological symptoms within 4 weeks of Cycle 1 Day 1.
-
Major surgery, other than diagnostic surgery, within 14 days prior to Cycle 1 Day 1, without complete recovery.
-
Active, uncontrolled bacterial, viral or fungal infections requiring systemic therapy.
-
Other protocol defined exclusion may apply
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Gabrail Cancer Center Research | Canton | Ohio | United States | 44718 |
| 2 | NEXT Oncology | Austin | Texas | United States | 78758 |
| 3 | NEXT Oncology | San Antonio | Texas | United States | 78229 |
Sponsors and Collaborators
- Kura Oncology, Inc.
Investigators
- Principal Investigator: David Sommerhalder, MD, NEXT Oncology
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- KO-TIP-011